<SEC-DOCUMENT>0000950170-25-086732.txt : 20250616
<SEC-HEADER>0000950170-25-086732.hdr.sgml : 20250616
<ACCEPTANCE-DATETIME>20250616161211
ACCESSION NUMBER:		0000950170-25-086732
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250612
FILED AS OF DATE:		20250616
DATE AS OF CHANGE:		20250616

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Rosenberg Anthony
		CENTRAL INDEX KEY:			0001466175
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39856
		FILM NUMBER:		251050203

	MAIL ADDRESS:	
		STREET 1:		C/O CULLINAN THERAPEUTICS, INC.
		STREET 2:		1 MAIN STREET SUITE 1350
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cullinan Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001789972
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813879991
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		ONE MAIN STREET
		STREET 2:		SUITE 1350
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-410-4650

	MAIL ADDRESS:	
		STREET 1:		ONE MAIN STREET
		STREET 2:		SUITE 1350
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cullinan Oncology, Inc.
		DATE OF NAME CHANGE:	20210225

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cullinan Management, Inc.
		DATE OF NAME CHANGE:	20210107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cullinan Oncology, LLC
		DATE OF NAME CHANGE:	20191001
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-06-12</periodOfReport>

    <issuer>
        <issuerCik>0001789972</issuerCik>
        <issuerName>Cullinan Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>CGEM</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001466175</rptOwnerCik>
            <rptOwnerName>Rosenberg Anthony</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CULLINAN THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>ONE MAIN STREET, SUITE 1350</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02142</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>8.95</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-06-12</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>38513</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-06-12</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>38513</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>38513</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Jacquelyn Sumer, Attorney-in-Fact</signatureName>
        <signatureDate>2025-06-16</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
